NCT02792400View on ClinicalTrials.gov

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

July 31, 2018

Conditions

Type 2 Diabetes

Interventions

DRUG

LY2403021

Glucagon receptor antagonist

DRUG

LY2403021 placebo

PROCEDURE

Standardised liquid meal

DRUG

Linagliptin

DPP-4-inhibitor

DRUG

Linagliptin placebo

DRUG

Empagliflozin

SGLT2-inhibitor

DRUG

Empagliflozin placebo

Trial Locations (1)

DK-2900

Center for Diabetes Research, Gentofte Hospital, Copenhagen University, Hellerup

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

University Hospital, Gentofte, Copenhagen

OTHER

NCT02792400 - The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors | Biotech Hunter | Biotech Hunter